Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection (MCC/CC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01114581
Recruitment Status : Completed
First Posted : May 3, 2010
Results First Posted : October 8, 2012
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):
Reckitt Benckiser LLC

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Care Provider, Investigator);   Primary Purpose: Treatment
Condition: Acute Respiratory Infection
Interventions: Drug: Mucinex
Drug: Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Guaifenesin Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
Placebo Given as 2 tablets

Participant Flow:   Overall Study
    Guaifenesin   Placebo
STARTED   19   19 
COMPLETED   19   19 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Guaifenesin Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
Placebo Given as 2 tablets
Total Total of all reporting groups

Baseline Measures
   Guaifenesin   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 19   19   38 
[Units: Participants]
Count of Participants
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      19 100.0%      19 100.0%      38 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
[Units: Years]
Mean (Standard Deviation)
 25.8  (6.0)   30.0  (11.94)   27.9  (9.56) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      9  47.4%      10  52.6%      19  50.0% 
Male      10  52.6%      9  47.4%      19  50.0% 
Region of Enrollment 
[Units: Participants]
United States   19   19   38 

  Outcome Measures

1.  Primary:   Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs   [ Time Frame: 3 hours following inhalation of radioactive tracer particles ]

2.  Secondary:   Guaifenesin AUC(0-3)   [ Time Frame: 3 hours following dose administration ]

3.  Secondary:   Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo.   [ Time Frame: Within 10 days of developing symptoms associated with a respiratory tract infection ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Gail Solomon, Director, Clinical Development
Organization: Reckitt Benckiser Inc.
phone: 973-404-2752

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Reckitt Benckiser LLC Identifier: NCT01114581     History of Changes
Other Study ID Numbers: 2010-MUC-01
First Submitted: April 28, 2010
First Posted: May 3, 2010
Results First Submitted: March 15, 2012
Results First Posted: October 8, 2012
Last Update Posted: November 6, 2017